Codexis (CDXS) Research & Development (2010 - 2026)
Codexis (CDXS) posted quarterly Research & Development of $11.4 million for Q1 2026, down 11.54% year-over-year from $12.9 million in Q1 2025, and down 2.33% quarter-over-quarter from $11.7 million in Q4 2025.
Codexis (CDXS) Research & Development (2010 - 2026) Analysis & Trends
Codexis' Research & Development history runs 17 years deep, the most recent figure standing at $11.4 million for Q1 2026.
- In Q1 2026, Research & Development fell 11.54% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $50.8 million (up 5.95% YoY), while the FY2025 annual figure was $52.3 million, up 13.06% from the prior year.
- Research & Development for Q1 2026 stood at $11.4 million, down from $11.7 million in the prior quarter.
- The five-year high for Research & Development was $21.8 million in Q3 2022, with the low at $11.2 million in Q4 2023.
- The 5-year median for Research & Development is $13.7 million (2023), against an average of $14.6 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development surged 68.52% in 2022, then plunged 42.94% in 2023.
- Codexis' Research & Development stood at $19.7 million in 2022, then tumbled by 42.94% to $11.2 million in 2023, then advanced by 7.7% to $12.1 million in 2024, then slipped by 3.12% to $11.7 million in 2025, then fell by 2.33% to $11.4 million in 2026.
- Business Quant data shows CDXS's Research & Development at $11.4 million in Q1 2026, $11.7 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | 11.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.71 Mn |
| Mar 31, 2026 | 11.45 Mn |
| Dec 31, 2025 | 11.72 Mn |
| Sep 30, 2025 | 13.87 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Mar 31, 2025 | 12.94 Mn |
| Dec 31, 2024 | 12.10 Mn |
| Sep 30, 2024 | 11.51 Mn |
| Jun 30, 2024 | 11.41 Mn |
| Mar 31, 2024 | 11.25 Mn |
| Dec 31, 2023 | 11.23 Mn |
| Sep 30, 2023 | 13.66 Mn |
| Jun 30, 2023 | 17.33 Mn |
| Mar 31, 2023 | 16.66 Mn |
| Dec 31, 2022 | 19.69 Mn |
| Sep 30, 2022 | 21.82 Mn |
| Jun 30, 2022 | 19.09 Mn |
| Mar 31, 2022 | 19.50 Mn |
| Dec 31, 2021 | 16.36 Mn |
| Sep 30, 2021 | 15.17 Mn |